Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Shares Pass Above Fifty Day Moving Average – Here’s Why

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $28.35 and traded as high as $30.86. Lakefront Biotherapeutics American Depositary Shares shares last traded at $30.58, with a volume of 156,201 shares traded.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Wall Street Zen lowered Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, May 26th. Finally, Zacks Research raised Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Lakefront Biotherapeutics American Depositary Shares currently has an average rating of “Hold” and a consensus price target of $36.50.

Lakefront Biotherapeutics American Depositary Shares Trading Up 0.8%

The business’s 50 day simple moving average is $28.35 and its 200 day simple moving average is $30.89. The firm has a market capitalization of $2.02 billion, a PE ratio of -21.69 and a beta of 0.25.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of ($1.27) by $1.52. The business had revenue of $8.75 million during the quarter, compared to the consensus estimate of $11.26 million. Analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -6.32 earnings per share for the current year.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

A number of institutional investors and hedge funds have recently modified their holdings of LKFT. Madison Avenue Partners LP increased its position in shares of Lakefront Biotherapeutics American Depositary Shares by 0.8% during the 4th quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company’s stock valued at $72,371,000 after purchasing an additional 17,394 shares during the last quarter. Ameriprise Financial Inc. lifted its position in Lakefront Biotherapeutics American Depositary Shares by 2,490.1% in the third quarter. Ameriprise Financial Inc. now owns 1,416,934 shares of the biotechnology company’s stock worth $49,083,000 after buying an additional 1,362,229 shares during the last quarter. UBS Group AG boosted its stake in Lakefront Biotherapeutics American Depositary Shares by 128.4% during the fourth quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock worth $11,427,000 after buying an additional 196,445 shares during the period. Millennium Management LLC boosted its stake in Lakefront Biotherapeutics American Depositary Shares by 121.9% during the fourth quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock worth $11,097,000 after buying an additional 186,452 shares during the period. Finally, Jane Street Group LLC increased its position in Lakefront Biotherapeutics American Depositary Shares by 2,245.7% during the first quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock valued at $2,783,000 after acquiring an additional 115,946 shares during the last quarter. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.